Immune-Onc Therapeutics and BeiGene have signed a clinical trial partnership and supply agreement to evaluate IO-108 and IO-202 with tislelizumab.
The move is part of Immune-Onc’s clinical development programmes in China.
Go deeper with GlobalData
IO-108 and IO-202 are Immune-Onc’s first-in-class myeloid checkpoint inhibitors while tislelizumab is BeiGene’s anti-PD-1 antibody.
Immune-Onc CEO Charlene Liao said: “The preclinical and clinical data to date of our first-in-class LILRB antagonists IO-108 and IO-202 have shown that there is great potential in combining our myeloid checkpoint inhibitors with T cell checkpoint inhibitors, such as tislelizumab, to potentially improve clinical outcomes.
“By expanding our reach with BeiGene in China, we have an opportunity to treat a broader array of patients with significant unmet medical needs.”
Under the partnership terms, the IO-108 and IO-202 clinical trials in China will be sponsored and funded by Immune-Onc, which will also retain its worldwide rights.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBeiGene will provide tislelizumab for these clinical trials.
BeiGene R&D global head Lai Wang said: “Based on strong preclinical and emerging clinical data, we believe there is good synergy between PD-1 and LILRB antagonists for the treatment of solid tumours.
“We look forward to working with Immune-Onc to explore the possibility of combination therapy with our products, which may bring more treatment options to cancer patients in China.”
The ongoing Phase I study of the fully human IgG4 monoclonal antibody IO-108 in adult patients with cancer in the US has concluded dose escalation.
In April this year, Immune-Onc Therapeutics announced the dosing of the first subject in its Phase I clinical trial designed to evaluate IO-202 for treating advanced solid tumour patients.
